Pfizer Seeks Creation of Federal Docket for Ibrance Patent Infringement Actions



DOCUMENTS
  • Motion


WASHINGTON, D.C. — Pfizer has asked the Judicial Panel on Multidistrict Litigation to create a federal docket for lawsuits in which it has accused 20 generic drug makers of infringing the patent for its breast cancer drug Ibrance, arguing that they all involve the same substantive claims and are seeking the same relief.

In a Feb. 18 motion, Pfizer notes that nine of the 10 actions are pending in the U.S. District Court for the District of Delaware; therefore, it seeks centralization in that district before Judge Colm F. Connolly. The remaining action is pending in the Southern District of …






UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Baby Food Litigation

April 08, 2021 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS



HarrisMartin's Webinar Series: Natural Disaster Litigation - Insurance and Beyond - Winter Storm Uri and Hurricane Sally

March 09, 2021 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS